Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (ROCK-PD)

NCT05931575 is registered in ClinicalTrials.gov with Technical University of Munich as lead sponsor.

NCT NCT05931575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05931575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (ROCK-PD)
Lead sponsor
Technical University of Munich
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2023
Completion date
August 24, 2026
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson´s disease